Growth in Diagnostics capitalize on rising demand for molecular diagnostics driven by respiratory, influenza, and GI pathogens. With FDA-cleared BioCode MDx-3000 system and expanding panels, there is cross-sell potential to existing microbiology and infectious disease customers, as well as international expansion opportunities given CE-Mark status.

New Panels Expansion leverage introductions of STI plus Resistance Panel and fungal panels to broaden the addressable market. Target hospitals, reference labs, and research institutions seeking multiplex solutions to streamline workflows and reduce time-to-result across infectious disease and antimicrobial resistance testing.

Strategic Partnerships deepen collaborations with distributors and healthcare manufacturers (e.g., Medline) to accelerate market penetration in US and global markets. Co-marketing and bundled offerings can widen product reach for MDx-3000 systems and related assays in diverse settings.

Executive & Capabilities capitalize leadership changes and CSO appointment to boost R&D credibility and regulatory strategy. Use this momentum to pursue larger multi-site deployments, regulatory approvals, and joint development projects with pharma and diagnostics players.

Financial Readiness with a revenue base of several tens of millions and ongoing investment, position sales teams to pursue large-volume contracts and multi-year service agreements. Highlight cost-per-result efficiencies and high multiplexing capacity to justify ROI for large lab networks and health systems.